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Summary A major form of drug resistance in tumour cells known as classical multidrug resistance (MDR) is
associated with the overexpression of the mdrl gene product, the membrane protein P-glycoprotein (P-gp),
which acts as an energy-dependent drug efflux pump. In this study the inheritance of P-gp expression was
examined using hybrids formed after somatic cell fusion between a drug-sensitive human T-cell leukaemia cell
line, CEM/CCRF, and a drug-resistant derivative, CEM/A7, which is characterised by a clonal chromosomal
duplication dup(7)(ql1.23q31.2). Fourteen hybrids, chosen at random, were analysed by reverse transcriptase-
polymerase chain reaction (RT-PCR) and by binding studies involving the monoclonal antibody MRK16,
which recognises an external P-gp epitope. Only two hybrids were positive for both MRK16 antibody labelling
and mdrl mRNA. Partial karyotypic analysis of all hybrids revealed that only the MRK16-positive hybrids
contained the duplication in chromosome 7 seen in the CEM/A7 parental MDR line. Therefore, P-gp
overexpression in the MRK16-positive hybrids may be linked to the inheritance of chromosome 7 from
CEM/A7 and possibly associated with the chromosome 7 abnormality.
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Although chemotherapy remains an important treatment
modality for patients with advanced malignancy, only a small
proportion are cured by currently available cytotoxic agents.
The majority of malignancies are either intrinsically drug
resistant or acquire resistance after initially responding to
chemotherapy. A variety of factors may influence the clinical
impact of any single cytotoxic agent, but drug resistance at
the genetic level is thought to be one of the most important
determinants in clinical outcome.
A major form of drug resistance, known as classical multi-
drug resistance (MDR), is characterised by cross-resistance to
a variety of structurally and functionally unrelated drugs
(Bradley et al., 1988). The phenotype is associated with the
overexpression of P-glycoprotein (P-gp), a high-molecular
weight membrane protein of approximately 170 kDa (Croop
et al., 1988). P-gp functions as an energy-dependent drug
efflux pump resulting in decreased intracellular accumulation
of cytotoxic agents in resistant cells. Consequently, the
regulation of P-gp expression in resistant tumour cells is the
focus of many studies.
The human P-gp molecule is encoded by the mdrl gene,
which has been localised to chromosome 7 (Fojo, et al.,
1986). Chromosome 7 abnormalities have been previously
described in MDR cells containing mdrl gene amplification
and overexpressing P-gp (Slovak et al., 1987; Nieuwint et al.,
1992). In these cells, P-gp overexpression was commonly
accompanied by various abnormalities of the long arm of
chromosome 7, usually with breakpoints close to the mdrl
locus, 7q21.1 (Nieuwint et al., 1992). However, it is currently
unknown whether the structural rearrangements of chromo-
some 7 observed in MDR cell lines actually lead to altera-
tions in the expression of P-gp.
It has been established that marker chromosomes can be
inherited by hybrid cells resulting from somatic cell fusions
(Palyi et al., 1994). Therefore, the clonal chromosomal dup-
lication of the region 7ql 1.23q31.2 that characterises the
MDR variant of the CEM/CCRF drug-sensitive cell line,
CEM/A7, (Zalcberg et al., 1994) provides a marker for the
investigation of the inheritance of chromosome 7 and P-gp
overexpression.
In the past, studies employing somatic cell fusion techni-
ques have been used to determine the dominance of the
classical MDR phenotype. Difficulties in the interpretation of
the results relate to the use of cells with complex phenotypes
involving more than one mode of drug resistance and the use
of a 'drug-sensitive' parental line, which in fact expressed low
levels of P-gp (Eijdems et al., 1992). Additionally, previous
findings suggesting that the classical MDR phenotype is
dominant, or at least co-dominantly expressed, have also
been complicated by the use of phenotypically unstable resis-
tant parental lines in which amplified copies of the mdrl gene
resided on unstable chromosomal elements (Akiyama et al.,
1985). In such studies, expression of mdrl genes harboured
on circular DNAs are not necessarily confined to the
regulatory constraints of cis-acting factors on chromosome 7.
In the present study, although the issue of the dominance
of mdrl gene expression is not addressed, the expression of
P-gp in hybrid cell lines was examined in a model designed to
overcome the issues that confounded previous somatic cell
fusion experiments. The sensitive parental line was truly P-gp
negative, as determined by the polymerase chain reaction
(PCR) while the resistant parental line overexpressed P-gp
without the concomitant amplification of the mdrl gene
(Zalcberg et al., 1994) seen in most classical MDR cell lines
used previously. Karyotypic analyses of chromosome 7 were
performed in the hybrid lines and cytotoxic agents were not
added to the post fusion medium thus avoiding any selective
pressure for expression of the MDR phenotype.
Materials and methods
Cell lines and culture conditions
The MDR variant of the CEM/CCRF line, CEM/A7 (Zalc-
berg et al., 1994) was used as the drug-resistant parental line
for the fusion experiments and was grown in 0.07 ig ml-'
doxorubicin (David Bull Laboratories, Melbourne, Aust-
ralia). Cells were grown in RPMI 1640 (Gibco Labs) supp-
lemented with 10% fetal calf serum (FCS, Flow Labs, Aust-
ralia) and 0.8 mM glutamine at 37TC, in a humidified
chamber in an atmosphere of 5% carbon dioxide in air.
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The cell line, CEM/CCRF (Foley et al., 1965) represented
the drug-sensitive parental line into which selective markers
were introduced. CEM/CCRF cells were cultured in increas-
ing concentrations of the purine antagonist, 2-amino-6-
mercaptopurine (6-thioguanine, Sigma Pharmaceuticals) and
finally maintained in medium containing 20fig ml-' 6-
thioguanine. The resulting cell line was unable to grow in
HAT medium, indicating a deficiency in the purine nucleo-
tide salvage pathway enzyme hypoxanthine-guanine phos-
phoribosyl transferase (HGPRT). The resulting HGPRT -/
CCRF cells were stably transfected with the bacterial
aminoglycoside phosphotransferase 3' (II) gene which confers
resistance to the antibiotic neomycin and its derivatives
(Hanchett et al., 1992). All cells were mycoplasma-free when
tested by the Gen-Probe mycoplasma assay (GEN-PROBE,
San Diego, CA, USA).
Transfection ofthe mutant drug-sensitive parent
HGPRT -/CCRF cells, in logarithmic growth phase, were
washed three times in cold, serum-free RPMI-1640 and
adjusted to a concentration of 2 x I07 cells ml- before
electroporation. Cells (500 !ld) were mixed with 20pg of pSV
2-neo plasmid DNA (Southern and Berg, 1982) and
incubated on ice for 5 min before electroporation at 270V
and 960 lF using a Gene Pulser (Bio-Rad Laboratories,
Richmond, CA, USA). The cells were then left on ice for
10min and resuspended in 6ml of complete medium. The
suspension was centrifuged at 800 r.p.m. for 1.5 min to
remove debris and the pellet was resuspended in 10ml of
complete medium. Cells were grown in non-selective medium
for 48 h, after which 400jig ml-1 of the neomycin analogue
geneticin sulphate (G418, Gibco Laboratories, Grand Island,
NY, USA) and 20ligml-' 6-thioguanine were added to the
medium.
Somatic cellfusions
Hybrids of drug-sensitive and -resistant cells were generated
by mixing HGPRT-/NeoR/CCRF (HNCCRF) sensitive cells
with CEM/A7 resistant cells, in logarithmic growth phase, at
a ratio of 1:5 yielding a total of 2 x 107 cells. Cells were
washed three times in serum-free RPMI-1640 to remove FCS
from the culture medium. Polyethylene glycol [PEG 4000,
0.8 ml, 50% w/v in phosphate-buffered saline (PBS), Boehr-
inger Mannheim] was added dropwise over 1 min to a
dispersed pellet and the suspension was incubated at 37°C for
3 min. To dilute out the PEG, 2 ml of serum-free RPMI 1640
was added over 1 min with gentle mixing. Serum-free
medium (8 ml) was then added and the cell clumps were spun
down at 500 r.p.m. for 3 min and resuspended in 40 ml of
complete medium.
The cells were plated out into 96-well plates (Flow Labs)
at a density of 5 x 104 cells per well and were incubated for
24 h in non-selective medium at 37°C. Selective medium
(100 dl of 1 x HAT: o0-6 M hypoxanthine, 4 x l0-5 M
aminopterin, 1.6 x l0-5 M thymine from ICN Flow, Califor-
nia, USA; 400 ytg ml-' G418) was added to each well.
Medium was replaced with fresh selective medium every 3
days. Resultant hybrids were expanded into 24-well plates
and from there into 25 cm2 tissue culture flasks (Flow Labs).
Growth assays
Growth assays for the CEM/CCRF, HNCCRF and CEM/
A7 lines were performed on actively growing cells in varying
concentrations of either doxorubicin or vinblastine (David
Bull Laboratories) in triplicate. The assays were performed as
previously described (Hu et al., 1990) with cells in logarith-
mic growth phase at a density of 5 x 104 cells ml-' seeded
into 24-well plates. After 3 days, cell counts were determined
using a Coulter Counter (Model DN, Coulter Electronics,
Luton, England). The IC50 value (the dose that inhibits cell
growth by 50% relative to untreated controls) was deter-
mined for each cell line for both drugs. Additionally, the
growth of cells in either HAT medium or varying concentra-
tions of G418 was assessed. Cells were plated out at a density
of 103 cells ml- and cell numbers determined following 7
and 14 days' incubation in HAT medium or 16 days' incuba-
tion in G418 at 37°C.
Similarly, drug resistance profiles for the parental CEM/
CCRF, HNCCRF a'nd CEM/A7 lines and four hybrid cell
samples were determined using actively growing cells in vary-
ing concentrations of the cytotoxic agent epirubicin (David
Bull Laboratories). Experiments were performed in triplicate
as described above.
MRK16 screening
Cellular expression of P-gp was determined using a FACScan
flow cytometer (Becton Dickinson, California, USA). The
assay involved the use of a monoclonal antibody, MRK16
(gift from Dr Tsuruo, Division of Experimental Chemo-
therapy, Japanese Foundation for Cancer Research), in a
method previously described (Wall et al., 1993) with minor
modifications. Briefly, exponentially growing cells (106
cells ml-') were pelleted. The pellet was dispersed and to one
tube 0.37 ,tg of the monoclonal antibody MRK16 was added.
To the other duplicate 1 tsg of the non-specific murine
monoclonal antibody, IgG 2a control (Becton Dickinson)
was added to act as a control. The tubes were then incubated
at room temperature for 20min. Each sample was washed
twice in complete medium and 0.5jg of a fluorescein-
conjugated goat anti-mouse antibody (Becton Dickinson) was
added. Samples were then incubated at room temperature for
20 min in the dark. Finally the cells were washed three times
in complete medium and analysed in the flow cytometer.
RNA extraction andpreparation ofcDNA
RNA was extracted from both the parental cell lines and
randomly selected hybrid cells using the guanidinium thio-
cyanate phenol chloroform method described by Chomczyn-
ski and Sacchi (1987). RNA (10fig) and 100 ng random
primers (Promega Corporation) were incubated at 70°C for
5 min and then quickly chilled on ice for 2 min. The volume
was adjusted to 20 tlI containing 50 mM Tris-HCI (pH 8.3),
5 mM each of dATP, dGTP, dCTP and dTTP, 75 mM potas-
sium chloride, 3 mm magnesium chloride, 5 mM dithioth-
reitol, 200 units of Superscript RNase H- Reverse Transcrip-
tase (Gibco-BRL), and incubated at 37°C for 1 h. The resul-
tant cDNA samples were diluted to 100 tli with distilled
water, heated to 90°C for 5 min and then stored at - 20°C.
RT-PCR
The primers P6 (TGCCTGGCAGCTGGAAGACAAATT-
CACAAAAT) and P7 (CAGACAGCAGCTGACAGTC-
CAAGAACAGGACTG) corresponded to nucleotides 545-
577 and 799-831 relative to the mdrl transcription initiation
site respectively. The primers used for the histone 3.3 gene,
HI (CCACTGAACTTCTGATTCGC) and H2 (GCGTGC-
TAGCTGGATGTCTT), annealed to nucleotides 282-301
and 476-495 respectively. PCR reactions (50 lI) contained
25 pmol of each primer pair. Other components were 10 mM
Tris-HCI, 1.5 mM magnesium chloride, 50 mM potassium
chloride, 100ngml-l gelatine at pH 8.3, 100.LM of each
dNTP, 1 unit of Taq polymerase (Boehringer Mannheim)
and 51l of cDNA. The PCR cycle consisted of a single
incubation at 95°C for 5 min, followed by 35 cycles of 94°C
for 30 s, 58°C for 60 s and 72°C for 60 s on an Omnigene
temperature cycler (Hybaid Limited, Middlesex, USA). The
PCR products were analysed on 3% Nusieve GTG agarose
(FMC BioProducts, Rockland, USA) gels.
Isolation ofgenomic DNA and PCR
Genomic DNA was extracted from the parental cell lines and
hybrid cells according to the isolation procedure outlined by
Laird et al. (1991). PCR followed the same protocol as aboveChromosome 7 and drug resistance
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except that primers P12 (GGAAGAGCCGCTACTCGA,
nucleotides 2-20) and P15 (GAAACTGTCAAGCATGCT,
nucleotides 464-446) were substituted for primers P6 and P7.
The PCR cycle consisted of 96°C for 2 min, 40 cycles of 95°C
for 45 s, 55°C for 1 min, 72°C for 2 min.
Cytogenetic analysis
Chromosome preparations were obtained using standard pro-
cedures (Webber and Garson, 1983) and G-banded chromo-
somes were assembled and described according to the Inter-
national System of Human Cytogenetic Nomenclature
recommendations (ISCN, 1991). Only chromosome 7 of each
hybrid was examined in detail since the karyotype from both
parental cells has been previously reported (Zalcberg et al.,
1994).
Results
Isolation and characterisation ofparental cell lines
Two selective markers were introduced into the sensitive,
parental cell line, CEM/CCRF to produce the HNCCRF cell
line for use in the fusion experiments. Initially, CEM/CCRF
cells were cultured in increasing concentrations of the purine
antagonist 6-thioguanine to select for cells deficient in the
purine nucleotide salvage pathway enzyme, HGPRT. These
cells were maintained in 20 ygml-' 6-thioguanine. Subse-
quently these HGPRT- mutant cells were electroporated with
the pSVneo plasmid and cultured in medium also containing
G418 (a neomycin analogue) to select for the HGPRT- and
G418-resistant double mutant referred to as HNCCRF.
Although a deletion or mutation in the HGPRT gene was
not specifically demonstrated, the fact that this cell line was
completely inhibited in HAT medium, suggests the HGPRT
gene product was non-functional.
Before cell fusion, the drug resistance profile for the two
parental cell lines was determined in order to see whether the
creation of the double mutant, HNCCRF, had altered the
drug resistance profile or induced expression of P-gp. The
HNCCRF mutant remained sensitive to doxorubicin and
vinblastine relative to the resistant cell line, CEM/A7. There
was a minor increase in doxorubicin resistance and a
decrease in vinblastine resistance relative to CEM/CCRF
cells (Table I).
To confirm that HNCCRF was truly negative for P-gp
expression, MRK16 binding analysis by flow cytometry was
conducted. As demonstrated in Table II, P-gp expression was
observed only in the CEM/A7 cell line. Both CEM/CCRF
Table I Drug resistance of parental cell lines to doxorubicin and
vinblastine
Cell lines
Drugs CEM/CCRF HNCCRF CEM/A7
Doxorubicin 8.6 ± 0.6 17.0 ± 1.0 357.0 ± 31.0
Vinblastine 1.9 ± 0.2 0.9 ± 0.1 37.0 ± 4.0
Results areexpressed asthe IC50determined asdescribed in Materials
and methods. Results represent the average concentration (ng ml-')
standard error calculated from three identical experiments.
and HNCCRF failed to express P-gp. These results were
confirmed by reverse transcriptase (RT)-PCR analysis of
RNA extracted from these cell lines. Although all cells con-
tained the mdrl gene, no mdrl mRNA was detected in the
CEM/CCRF or HNCCRF lines (Table II) thus establishing
HNCCRF as a P-gp-negative, drug-sensitive cell line with
respect to the vinca alkaloids, drugs normally considered
substrates for P-gp.
The growth of the HNCCRF cells was strongly inhibited
in HAT medium but both CEM/CCRF and CEM/A7 grew
well in the presence of HAT (data not shown). Conversely,
G418 at concentrations as high as 800ILgmlm' had little
effect on the survival of HNCCRF cells (data not shown). In
comparison, both CEM/CCRF and CEM/A7 were incapable
of growth in the presence of G418 at concentrations above
100[igml-'. In summary, these data indicate that medium
containing both HAT and G418 would completely inhibit the
growth of the HNCCRF and CEM/A7 parental lines respec-
tively, allowing only true hybrids to grow after somatic cell
fusion.
MRK16 labelling and PCR analysis ofsomatic cell hybrids
Control fusions involving the crosses CEM/CCRF x CEM/
A7, CEM/A7 x CEM/A7 and HNCCRF x HNCCRF yie-
lded no viable hybrids as was expected. However, fusions
between HNCCRF cells and CEM/A7 cells produced many
viable hybrids.
Fourteen hybrids were randomly selected for further
analysis. Preliminary analyses were carried out 5 weeks after
fusion to ensure that parental cells had been eliminated by
the post fusion selection medium. Ploidy analyses at this time
indicated that chromosomal segregation had already taken
place since most hybrids had a tetraploid complement of
chromosomes, similar to that of both parental lines (data not
shown). Unfortunately, most hybrids were not of sufficient
confluency for analysis until 10 weeks after fusion.
Of the 14 hybrids analysed for MRK16 binding, only two
were positive (ICIO, 2GI0). Relative to that observed in the
CEM/A7 parent (100%), the binding of MRK16 in these
hybrids was 86% and 75% respectively (Table II). The
remainder of the hybrids were all negative for MRK16 bin-
ding, indicating no P-gp expression. The hybrids were all
stable with respect to viability and MRK16 status.
RNA was extracted from 11 of the hybrids and was
analysed by RT-PCR (Figure 1). The only hybrids to yield a
PCR product of the expected size were ICIO and 2GI0, the
same hybrids that gave a positive MRK16 labelling result.
Primers to the histone 3.3 gene provided an internal control
ensuring that RNA was present in each sample. Genomic
DNA extracted from the same hybrids was also analysed by
PCR (data not shown) using primers that anneal to the
promoter region of the mdrl gene. All hybrids were found to
be positive for mdrl genomic DNA suggesting that all hyb-
rids had retained the mdrl gene.
Drug resistance profile ofthe hybrid cells
Resistance to epirubicin was determined in the two P-gp-
positive hybrids, lCIO and 2GI0, two hybrid cell samples
negative for the expression of P-gp, 2H6 and 4G9, as well as
r-1
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Table II MRK16 binding analysis of parental and P-gp-positive hybrid cells
Cell line MRK16 binding' MRK16positivityb RT-PCR'
CEM/A7 99 100 + + +
CEM/CCRF 0 0
CCRF/HGPRT- 0 0
HNCCRF 0 0
ICIO 99 86 +
2G10 93 75 +++
a Indicates the percentage ofcells that were positive for MRK16 binding compared
with the isotype control (see Materials and methods). b Positivity is the degree of
MRK16 binding compared with that of the CEM/A7-positive control. c PCR on
cDNA using primers 6 and 7 (see Materials and methods).%-%- Chromosome 7 and drug resistance
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Figure 1 Ethidium bromide-stained agarose gels showing the
RT-PCR results from parental cell lines as well as 11 hybrids
demonstrating the presence of mdrl message. Histone is used as
an internal control.
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Figure 2 Percentage change in the number of the parental CEM/
CCRF, HNCCRF and CEM/A7 cells as well as the hybrids
ICIO, 2GI0, 2H6 and 4G9 as a function of increasing concentra-
tions of epirubicin. 0, CEM/CCRF; O, HNCCRF; 0, CEM/
A7; A, ICIO; E, 2G10; *, 2H6; @, 4G9N.
the parental cell lines CEM/CCRF, HNCCRF and CEM/A7
(Figure 2). The two hybrid cells that expressed both mdrl
mRNA and P-gp also exhibited a resistance to the cytotoxic
drug, epirubicin, similar to the MDR cell line CEM/A7. In
contrast, the two drug-sensitive cell lines, CEM/CCRF and
HNCCRF and the two P-gp-negative hybrids, 2H6 and 4G9,
were sensitive to epirubicin.
Cytogenetic analysis ofhybrids
The parental cell lines used in this study have been previously
karyotyped (Zalcberg et al., 1994). Both contain mainly near-
tetraploid metaphases with the modal number of
chromosomes ranging from 89 to 102. Structural changes in
both cell lines are consistent as the CEM/A7 line was
originally derived from the CEM/CCRF line. The main
difference between the parental cell lines is that the CEM/A7
cell line contains a duplication in chromosome 7,
dup(7)(ql 1.23q31.2). This duplication appears to include the
mdrl gene locus which is located at 7q21.1 (Trent and Callen,
1991). Cytogenetic analysis of the hybrids revealed that only
the MRK16-positive hybrids 2G10 and ICIO contained
abnormalities of chromosome 7. The specific abnormality
was identified to be the same as that seen in the CEM/A7 cell
line, a duplication involving the region qI 1.23q31.2. All other
hybrids contained only normal copies of chromosome 7 as
observed in the drug-sensitive parental line, CEM/CCRF.
Figure 3 shows a normal chromosome 7 as well as the
abnormal chromosome 7 in the hybrid lCIO.
Discussion
In a previous report, we described the derivation of the
drug-resistant CEM/A7 cell line in which we identified an
abnormality on chromosome 7 (Zalcberg et al., 1994). This
chromosomal abnormality provided us with a unique marker
for studying the inheritance of chromosome 7 and drug
resistance in hybrids obtained from somatic cell fusion
experiments.
A double mutant from the drug-sensitive human T-cell
leukaemia cell line CEM/CCRF was created for use in fusion
experiments. The CEM/CCRF parental cell line was selected
because it lacked P-gp expression as determined by MRK16
labelling and RT-PCR analysis, thus providing a truly P-gp-
negative, drug-sensitive parent. In contrast, the drug-resistant
CEM/A7 cell line was strongly positive for P-gp as deter-
mined by both of these assays. The double mutant HNC-
CRF, was deficient in the HGPRT enzyme and carried the
gene for neomycin resistance. Examination of the growth
assays performed in the presence of increasing concentrations
of doxorubicin and vinblastine clearly showed that HNC-
CRF essentially maintained its sensitivity to these drugs,
a b
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Figure 3 (a) On the left is an idiogram of a normal chromosome
7 together with a normal copy of chromosome 7 from the hybrid
cell line ICIO. (b) On the left is an idiogram of the derivative
chromosome 7 and a copy of the der(7) from I1C0 with the
duplicated region 7qll.23 to 7q31.2 indicated.
having an IC50 value similar or very close to that of the
CEM/CCRF parental cell line from which it was derived
(Table II) In contrast, the CEM/A7 line demonstrated resis-
tance to both drugs, especially to doxorubicin, the drug
against which it was primarily selected.
Growth of the HNCCRF and CEM/A7 cell lines was
abolished in selective medium containing both HAT and
G418, allowing the selection of hybrids that would have had
to inherit the HGPRT enzyme from the CEM/A7 cell line
and neomycin resistance from the HNCCRF cell line. This
selection procedure was relatively slow, requiring about 10
weeks for most hybrids to be numerous enough for charac-
terisation and ploidy analysis 5 weeks after fusion indicated
that chromosomal segregation had already taken place (data
not shown). However, compared with the cytotoxic drugs
used by other groups (Ling and Baker, 1978; Eijdems et al.,
1992; McLean et al., 1993), this selection procedure was less
likely to influence the P-gp status of resulting hybrids.
Since chromosomal segregation had occurred in the hyb-
rids, it was possible that the absence of P-gp expression in
the MRK16-negative hybrids was due to the loss of the mdrl
gene. However, PCR analysis of genomic DNA (data not
shown) confirmed the presence of the mdrl gene in all hyb-
rids, including those that failed to demonstrate P-gp expres-
sion. In contrast, RT-PCR analysis carried out on the same
cells indicated that mdrl mRNA was only detectable in the
two MRK16-positive hybrids, ICIO and 2G10 (Figure 1).
IChromosome 7 and drug resistance
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The MRK16 binding results (Table lI) indicate higher P-gp
positivity in the ClIO hybrid sample as compared with that
of 2G10. This is supported by the functional analysis of drug
resistance to the cytotoxic agent epirubicin (Figure 2) show-
ing a higher IC,-, value for ICI0 than for 2G10 (600 ngmVm
and 430 ngml- respectively.) suggesting that the hybrid
ICIO was more drug resistant than 2GI1. at least to
epirubicin. In contrast. the RT-PCR analysis (Figure 1) suz-
gested that the expression of midrl mRNA was in fact higher
in the 2G10 hvbrid. However. the PCR technique used in this
study was not quantitative and therefore the intensity of the
bands is not indicative of the level of mRNA expression.
Also. previous investigations have shown that it is possible
for P-gp to be overexpressed wvithout a simultaneous increase
in mdrl mRNA levels (Zhao et al.. 1994). Hence the RT-
PCR anal-sis merely indicates the presence or absence of
rmdrl mRNA.
Although the post fusion selection procedure was lengthy.
preliminary characterisation of another group of hybrids dur-
ing this time revealed strong MRK16 positivity. However.
these hybrids were not viable at 10 weeks (data not shown).
Similarly, in another group of hy%brids that contained a com-
bination of both MRK16-positive and -negative cells. only
the negative cells were present 10 weeks after fusion. This
apparent grow-th advantage of MRK16-negative cells and
unstable MDR phenotype in the absence of selective pressure
is not a new phenomenon. Ling and Baker (1978) added
graded concentrations of colchicine to their post fusion selec-
tion medium but also noted that h-brids lost their resistance
when cultured in the absence of colchicine. Akivama et al.
(1985) tested hy-brids grown in the absence of cv-totoxic
agents for functional resistance at 9 and 13 weeks after
fusion and demonstrated a loss of resistance. They suggested
that unstable. extrachromosomal genetic elements in the
parental cells may be responsible for this observation. How-
ever. in the present study the drug-resistant CEM A7 cell line
has a stable phenotype. When cultured in the absence of
cVtotoxic agents for more than 12 months. the cells still
overexpressed P-gp. althouah at a reduced level (Zalcberg et
al.. 1994).
CN-togenetic analy-sis of chromosome 7 in all 14 hy-brid cell
lines revealed the same duplication. dup(7Nqll.23q31.2) in
just two hvbrids. 2GI0 and lCIO. This abnormality appeared
to involve the rndrl locus at 7q21.1. The abnormality was
identical to that observed in the drug-resistant CEM A7
parental cell line (Zalcberg et al.. 1994). All other hy-brids
contained only normal copies of chromosome 7 as seen in the
drug-sensitive parental cell line. CEM CCRF. The two hvb-
rids with the dup(7q) kar-otypic abnormality were the onlv
two hy-brids to express P-gp and rnzdrl mRNA based on
MRK16 labelling and RT-PCR assays respectively. As these
two hybrids and CEM A7 overexpress P-gp and contain the
same duplication in chromosome 7. it would appear that
P-gp overexpression may be linked to the inheritance of the
abnormal chromosome 7 from the drug-resistant parental cell
line. CEM A7. While the inheritance of other chromosomal
factors from the CEM A7 line cannot be excluded as the
cause for increased expression of P-ep. we believe the data
sugaest that the common karyotypic abnormalities in
chromosome 7 may be the causal factor.
Although the duplicated region observed in the CEM A7
cell line has not been characterised. it provides a marker w-ith
which to study the inheritance of chromosome 7. It is un-
known whether the association shown in our data betu-een
the overexpression of P-gp and the inheritance of chromo-
some 7 from a resistant cell line is causally linked. however
we are currently attempting to map the duplication and site
of insertion of this duplication in the drug-resistant CEM A7
cell line to further our know-ledge of this chromosomal
abnormality.
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